On 10th March 2021, GeoVax Labs Inc. (GOVX) got invited to present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference that is to be held on 17th-18th March 2021. The company will present its recent developments in vaccine research and GeoVax’s immunotherapy. The next day, GeoVax’s stock went up by 15.38% to close at $5.55.
GeoVax Labs, Inc.
GeoVax is a biotech company whose primary goal is to develop effective and safe vaccines and immunotherapies against various infectious diseases such as Ebola and Zika Virus, and cancers. The company was established primarily to develop a vaccine for curing HIV-1. Still, eventually, the company moved on to create vaccines for various human severe diseases for which there does not exist a cure. According to GeoVax, the vaccines they make are developed on a sturdy, safe, suitable for repeated use and affordable for both routine vaccination and in case of an epidemic. GeoVax’s HIV program is now successfully advancing towards multiple human clinical trials, and its other programs are at different stages of pre-clinical testing.
GeoVax’s fight against the Epidemic
On 11th January 2021, GeoVax Labs In. announced that a part of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), has awarded them the grant to develop a vaccine to help fight against the worldwide pandemic, COVID-19. GeoVax is currently working on developing a vaccine that will help provide a prolonged protective immunity against the COVID-19 and avoid the potential side effects of the vaccine. Later on 10th March 2021, GeoVax Labs Inc. (GOVX) got invited to present at the Maxim Group’s Inaugural Emerging Growth Virtual Conference that is to be held on 17th-18th March 2021. During the virtual conference, the chairman and CEO of GeoVax Labs Inc., David Dodd, will overview their progress in vaccine research and immunotherapy, emphasisingGeoVax’s COVID-19 vaccine program and cancer immunotherapy programs. Mark Newman, Ph.D., the company’s ChiefScientific Officer, will also be a part of the panel discussion regarding its programs’ developments. Investors have the option of attending the virtual conference by registering and can also request to arrange a one-to-one meeting with the company’s CEO after the panel concludes.
All things considered
In the light of the given information, investors reacted positively to the news of GeoVax presenting at the virtual conference and the fact that they will be allowed to attend the meeting and have a one-to-one discussion with Mr. Dodd after the session has concluded.
